Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH2 Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Not applicableUnknownNCT03204838
What this trial is testing

IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients

Who this might be right for
Acute Myeloid Leukemia (AML)
Hospital General de Mexico 100
Large-scale testing (Phase 3)Active Not RecruitingNCT04164901
What this trial is testing

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Who this might be right for
Grade 2 GliomaResidual GliomaRecurrent Glioma
Institut de Recherches Internationales Servier 331
Early research (Phase 1)Study completedNCT02481154
What this trial is testing

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

Who this might be right for
Glioma
Institut de Recherches Internationales Servier 95
Not applicableLooking for participantsNCT07608003
What this trial is testing

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

Who this might be right for
Gliomas Harboring IDH1 and/or IDH2 MutationsGlioma Glioblastoma MultiformeGlioma of Brainstem+3 more
Xiangya Hospital of Central South University 500
Early research (Phase 1)UnknownNCT04272957
What this trial is testing

HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms

Who this might be right for
Acute Myeloid Leukemia
Hutchison Medipharma Limited 75
Testing effectiveness (Phase 2)Active Not RecruitingNCT04203316
What this trial is testing

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Children's Oncology Group 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT03212274
What this trial is testing

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmGlioblastomaRecurrent Cholangiocarcinoma+4 more
National Cancer Institute (NCI) 89
Large-scale testing (Phase 3)Active Not RecruitingNCT03839771
What this trial is testing

Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland 968
Early research (Phase 1)WithdrawnNCT04955938
What this trial is testing

Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Who this might be right for
IDH MutationIDH1 MutationIDH2 Gene Mutation+2 more
University of Chicago
Early research (Phase 1)UnknownNCT04806659
What this trial is testing

SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia

Who this might be right for
Acute Myelogenous Leukemia
Nanjing Sanhome Pharmaceutical, Co., Ltd. 41
Early research (Phase 1)Active Not RecruitingNCT04603001
What this trial is testing

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)+1 more
Eli Lilly and Company 260
Testing effectiveness (Phase 2)Looking for participantsNCT06577441
What this trial is testing

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Who this might be right for
Myelodysplastic Syndrome
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT03744390
What this trial is testing

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromesLeukemia Acute Myeloid
Groupe Francophone des Myelodysplasies 68
Not applicableStudy completedNCT02986620
What this trial is testing

Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
AML, Adult
Gruppo Italiano Malattie EMatologiche dell'Adulto 388
Large-scale testing (Phase 3)Study completedNCT02577406
What this trial is testing

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Who this might be right for
Leukemia, MyeloidIsocitrate Dehydrogenase
Celgene 319
Testing effectiveness (Phase 2)Ended earlyNCT03303950
What this trial is testing

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Who this might be right for
AnemiaASXL1 Gene MutationEZH2 Gene Mutation+7 more
University of Utah 6